- A
Anixa Biosciences, Inc.
- Emily Garr Gottschalk
Emily Garr Gottschalk is the Founder and CEO of The Garr Group, an entertainment and product development company established in 1998, with a successful launch of TGG Direct in 2007. Currently, Emily serves as a Director at Anixa Biosciences, a biotech firm focused on tackling cancer and infectious diseases. Additionally, as Executive Vice President of Sales at Ideation USA LLC, Emily leads efforts to create innovative consumer products through exclusive agreements with global patent-holders and designers. Emily's earlier experience includes marketing leadership roles at MarketSource Inc., Zany Brainy, Four Seasons Hotels and Resorts, and Marriott International, where substantial revenue and marketing strategies were developed. Emily holds a Bachelor of Science degree in Hotel Administration-Marketing from Cornell University.
Org chart
Teams
This person is not in any teams
Offices
Anixa Biosciences, Inc.
Anixa Biosciences (NASDAQ:ANIX) is a clinical stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company’s vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer--specifically triple negative breast cancer (TNBC), the most lethal form of the disease--as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.
